CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models

Background Glioblastoma (GBM) is a devastating primary brain tumor with a highly immunosuppressive tumor microenvironment, and treatment with oncolytic viruses (OVs) has emerged as a promising strategy for these tumors. Our group constructed a new OV named Delta-24-ACT, which was based on the Delta-...

Ful tanımlama

Kaydedildi:

Detaylı Bibliyografya
Asıl Yazarlar:	Hong Jiang, Sandra Hervás-Stubbs, Sara Labiano, Candelaria Gomez-Manzano, Juan Fueyo, Marta Alonso, Zhihong Chen, Montserrat Puigdelloses, Marc Garcia-Moure, Virginia Laspidea, Marisol Gonzalez-Huarriz, Marta Zalacain, Lucia Marrodan, Naiara Martinez-Velez, Daniel De la Nava, Iker Ausejo, Guillermo Herrador, Dolores Hambardzumyan, Ana Patino Garcia, Jaime Gállego Pérez-Larraya
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	BMJ Publishing Group 2021-07-01
Seri Bilgileri:	Journal for ImmunoTherapy of Cancer
Online Erişim:	https://jitc.bmj.com/content/9/7/e002644.full
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models

Benzer Materyaller